TABLE 2. Route of JYNNEOS vaccine administration among persons with mpox* vaccinated† ≥14 days before illness onset§ compared with expected proportions¶ — 14 U.S. jurisdictions,**,†† July 31–October 1, 2022.
| Route of vaccine administration§§ | Observed no. (%) | Expected no. (%) | p-value¶¶ |
|---|---|---|---|
| Subcutaneous |
263 (87.1) |
253 (83.0) |
0.28 |
| Intradermal | 39 (12.9) | 52 (17.0) |
Abbreviations: mpox = monkeypox; PCR = polymerase chain reaction.
* Confirmed (presence of Monkeypox virus DNA by PCR testing or next-generation sequencing of a clinical specimen or isolation of Monkeypox virus in culture from a clinical specimen) and probable (presence of Orthopoxvirus DNA by PCR testing, or Orthopoxvirus using immunohistochemical or electron microscopy or detectable levels of anti-Orthopoxvirus immunoglobulin M antibody) mpox cases.
† Receipt of ≥1 dose of JYNNEOS vaccine.
§ Earliest date available for each case; might include illness onset, specimen collection, laboratory test completion, admission, diagnosis, discharge, case investigation start date, or date first electronically submitted or reported to the county, state, or public health department.
¶ Based on vaccine administration data submitted by participating jurisdictions. The distribution of route of administration among vaccinated persons was summarized by week and applied to weekly case counts.
** California, Connecticut, District of Columbia, Florida, Illinois, Kansas, Louisiana, Massachusetts, Minnesota, New Mexico, New York (excluding New York City), Tennessee, Utah, and Wisconsin.
†† Jurisdictions were included if age and sex assigned at birth or gender identity was available for ≥70% of cases reported, vaccination status was available for ≥50% of cases in men (defined by either sex assigned at birth or gender identity) aged 18–49 years or the jurisdiction confirmed cases are linked to immunization registry entries, route of administration was complete for >80% of cases occurring ≥14 days after receipt of dose 1, and deidentified vaccine administration data were submitted to CDC.
§§ Limited to persons vaccinated ≥14 days before illness onset with recorded route of administration as subcutaneous or intradermal. One person with mpox who was vaccinated ≥14 days before illness onset was reported to have another route of vaccine administration. Route of administration was unknown for 39 persons with mpox who were vaccinated ≥14 days before illness onset; 33 persons who received dose 1 on or before August 9, 2022, were assumed to have received subcutaneous vaccination.
¶¶ Pearson’s chi-square test comparing observed and expected proportions of route of administration among cases with approved or authorized route of administration.